Nuvectis Pharma, Inc. Cash flow Statement
Figures in Million
Consolidated Cash Flow Results
Dec'25
Dec'24
Dec'23
Dec'22
Dec'21
Dec'20
No of Months
12
12
12
12
12
12
Profit Before Tax
-26.00
-19.00
-22.00
-19.00
-12.00
0.00
Adjustment
0.00
0.00
0.00
0.00
0.00
0.00
Changes In working Capital
4.00
1.00
1.00
3.00
1.00
0.00
Cash Flow after changes in Working Capital
0.00
0.00
0.00
0.00
0.00
0.00
Cash Flow from Operating Activities
-16.00
-12.00
-15.00
-13.00
-9.00
0.00
Cash Flow from Investing Activities
0.00
0.00
0.00
0.00
0.00
0.00
Cash Flow from Financing Activities
29.00
11.00
15.00
27.00
15.00
0.00
Net Cash Inflow / Outflow
13.00
0.00
0.00
14.00
5.00
0.00
Opening Cash & Cash Equivalents
0.00
0.00
0.00
0.00
0.00
0.00
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0.00
0.00
0.00
0.00
0.00
0.00
Cash & Cash Equivalent of Subsidiaries under liquidations
0.00
0.00
0.00
0.00
0.00
0.00
Translation adjustment on reserves / op cash balances foreign subsidiaries
0.00
0.00
0.00
0.00
0.00
0.00
Effect of Foreign Exchange Fluctuations
0.00
0.00
0.00
0.00
0.00
0.00
Closing Cash & Cash Equivalent
0.00
0.00
0.00
0.00
0.00
0.00
Figures in USD Million
Seasonal companies are compared with the same quarter last year
Seasonal companies are compared with the same quarter last year
Compare Cash Flow Results of Nuvectis Pharma, Inc.
Figures in Million
consolidated Cash Flow Results
Change(USD)
Change(%)
Profit Before Tax
-26.442
-659.849000007215
633.00
95.99%
Adjustment
0
0
0.00
0.00%
Changes In working Capital
4.401
-6.4750000000708
10.00
167.97%
Cash Flow after changes in Working Capital
0
0
0.00
0.00%
Cash Flow from Operating Activities
-16.009
-102.675000001123
86.00
84.41%
Cash Flow from Investing Activities
0
-109.127000001193
109.00
100.00%
Cash Flow from Financing Activities
29.11
269.481000002947
-240.00
-89.20%
Net Cash Inflow / Outflow
13.101
57.795000000632
-44.00
-77.33%
Opening Cash & Cash Equivalents
0
0
0.00
0.00%
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0
0
0.00
0.00%
Cash & Cash Equivalent of Subsidiaries under liquidations
0
0
0.00
0.00%
Translation adjustment on reserves / op cash balances foreign subsidiaries
0
0
0.00
0.00%
Effect of Foreign Exchange Fluctuations
0
0.116000000001268
0.00
-100.00%
Closing Cash & Cash Equivalent
0
0
0.00
0.00%
Cash Flow - Snapshot (Consolidated) - Dec'25
YoY Growth in year ended Dec 2025 is -30.72% vs 23.24% in Dec 2024
Dec'25
Dec'24
Change(%)
Cash Flow from Operating Activities
-16.01
-12.25
-30.72%






